amongSecurities Purchase Agreement • May 15th, 2003 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Delaware
EXHIBIT 4.2 INVESTOR RIGHTS AGREEMENTRights Agreement • May 15th, 2003 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Delaware
FORM OF UNDERWRITING AGREEMENT (Equity Primary Offering; Over Allotment Option; S-3) SEATTLE GENETICS, INC. 10,000,000 Shares of Common Stock Underwriting AgreementSeattle Genetics Inc /Wa • January 18th, 2008 • Biological products, (no disgnostic substances) • New York
Seattle Genetics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 10,000,000 shares of common stock, par value $0.001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,500,000 shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are herein referred to as the “Stock”.
SEAGEN INC. AND _____________, AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF __________Warrant Agreement • December 29th, 2020 • Seagen Inc. • Biological products, (no disgnostic substances) • New York
THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between SEAGEN INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
UNDERWRITING AGREEMENT SEATTLE GENETICS, INC. 7,142,858 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • July 24th, 2019 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York
Seattle Genetics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 7,142,858 shares of common stock, par value $ 0.001 per share (the “Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,071,428 shares of Common Stock of the Company solely to cover over-allotments (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
SEAGEN INC. AND _____________, AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF __________Warrant Agreement • December 29th, 2020 • Seagen Inc. • Biological products, (no disgnostic substances) • New York
THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between SEAGEN INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
EXHIBIT 10.2 EXECUTION COPY OPTION AGREEMENT, dated as of May 12, 2003 among SEATTLE GENETICS, INC., a Delaware corporation (the "Company"), and the other parties hereto (each an "Optionee"). In order to induce the Optionees to agree to purchase from...Option Agreement • May 15th, 2003 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Delaware
AGREEMENT AND PLAN OF MERGERAgreement and Plan of Merger • January 31st, 2018 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Delaware
This Agreement and Plan of Merger (this “Agreement”), dated as of January 30, 2018, is among Seattle Genetics, Inc., a Delaware corporation (“Parent”), Valley Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Sub”), and Cascadian Therapeutics, Inc., a Delaware corporation (the “Company”). Capitalized terms not otherwise defined herein shall have the respective meanings set forth in Annex A and Exhibit A attached hereto, as applicable.
RECITALS:Executive Employment Agreement • March 28th, 2003 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Washington
EXHIBIT 4.1 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER...Seattle Genetics Inc /Wa • May 15th, 2003 • Biological products, (no disgnostic substances) • Delaware
AMENDMENT NO. 1, dated as of May 14, 2003 (this "Amendment No. 1"), to the Securities Purchase Agreement, dated as of May 12, 2003, (the "Purchase Agreement"), among SEATTLE GENETICS, INC., a Delaware corporation (the "Company") and the purchasers...Securities Purchase Agreement • May 15th, 2003 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York
SEATTLE GENETICS, INC. Common Stock UNDERWRITING AGREEMENT dated March 29, 2006Underwriting Agreement • March 30th, 2006 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 11th, 2015 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York
This Registration Rights Agreement (this “Agreement”) is made as of September 10, 2015, by and between Seattle Genetics, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • October 27th, 2016 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Washington
THIS AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of the 26th day of October, 2016, by and between SEATTLE GENETICS, INC., a Delaware corporation (“Company”) and Clay B. Siegall (“Executive”).
AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • July 31st, 2020 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Washington
THIS AMEDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of the 15th day of April, 2020, by and between SEATTLE GENETICS, INC., a Delaware corporation (“Company”) and Charles Romp (“Executive”).
SEATTLE GENETICS, INC. 11,000,000 Shares of Common Stock Underwriting AgreementSeattle Genetics Inc /Wa • August 12th, 2009 • Biological products, (no disgnostic substances) • New York
Seattle Genetics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 11,000,000 shares of common stock, par value $0.001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,650,000 shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are herein referred to as the “Stock”.
SEATTLE GENETICS, INC. 5,740,000 Shares of Common Stock Underwriting AgreementSeattle Genetics Inc /Wa • January 28th, 2009 • Biological products, (no disgnostic substances) • New York
Seattle Genetics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the one or more several Underwriters listed in Schedule 1 hereto (whether one or more, the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 5,740,000 shares of common stock, par value $0.001 per share, of the Company (the “Shares”). The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are herein referred to as the “Stock”.
2- 1.2 Board of Directors. Executive shall become a member of the Board of Directors of the Company on the Start Date. The Board of Directors of the Company shall take whatever steps are necessary to continue to nominate Executive for election to the...Executive Employment Agreement • February 15th, 2023 • Seagen Inc. • Biological products, (no disgnostic substances)
AGREEMENT AND PLAN OF MERGER by and among PFIZER INC., ARIS MERGER SUB, INC. and SEAGEN INC., Dated as of MARCH 12, 2023Agreement and Plan of Merger • March 13th, 2023 • Seagen Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of March 12, 2023, is by and among Pfizer Inc., a Delaware corporation (“Parent”), Aris Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Seagen Inc., a Delaware corporation (the “Company”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 1st, 2017 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York
This Registration Rights Agreement (this “Agreement”), dated as of February 10, 2017, by and between Immunomedics, Inc., a Delaware corporation (the “Company”), and Seattle Genetics, Inc., a Delaware corporation (together with its permitted successors and assigns, the “Purchaser”).
ContractEquity Incentive Plan Stock Option Agreement • October 28th, 2021 • Seagen Inc. • Biological products, (no disgnostic substances) • Delaware
WARRANT AGREEMENTWarrant Agreement • May 1st, 2017 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York
WARRANT AGREEMENT, dated as of February 16, 2017 (this “Agreement”), by and among Immunomedics, Inc., a Delaware corporation (the “Company”), and Broadridge Corporate Issuer Solutions, Inc., a Pennsylvania corporation (the “Warrant Agent”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 9th, 2007 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Washington
THIS EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of the 22nd day of May, 2006, by and between SEATTLE GENETICS, INC., a Delaware corporation (“Company”), and Pamela A. Trail (“Executive”).
LICENSE AGREEMENTLicense Agreement • November 26th, 2010 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Florida
This License Agreement (the “Agreement”) is entered into and made effective the 20th day of September, 1999 (the “Effective Date”) between UNIVERSITY OF MIAMI and its School of Medicine, whose principal place of business is at 1600 N.W. 10th Avenue, Miami, Florida 33136 (hereinafter referred to as “LICENSOR”) and Seattle Genetics, Inc., whose principal place of business is at 22215 26th Avenue S.E., Suite 3000, Bothell, Washington 98021, hereinafter referred to as “LICENSEE”).
SEATTLE GENETICS, INC. AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT2007 Equity Incentive Plan Stock Option Agreement • October 26th, 2018 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Delaware
THIS STOCK OPTION AGREEMENT (the "Agreement") dated %%OPTION_DATE,'MM/DD/YYYY'%-% ("Grant Date") between Seattle Genetics, Inc., a Delaware corporation (the "Company"), and %%FIRST_NAME%-% %%MIDDLE_NAME%-% %%LAST_NAME%-% ("Optionee"), is entered into as follows:
STOCK PURCHASE AGREEMENTStock Purchase Agreement • May 1st, 2017 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York
This Stock Purchase Agreement (this “Agreement”) is dated as of February 10, 2017 (the “Effective Date”), by and between Immunomedics, Inc., a Delaware corporation (the “Company”), and Seattle Genetics, Inc., a Delaware corporation (together with any valid assignees of its rights hereunder pursuant to Section 5.6, the “Purchaser”).
AMENDED AND RESTATED DEVELOPMENT AND LICENSE AGREEMENT GENENTECH, INC. AND SEATTLE GENETICS, INC.Development and License Agreement • March 6th, 2001 • Seattle Genetics Inc /Wa • Services-commercial physical & biological research • Washington
This Amended and Restated Development and License Agreement (the "Agreement") is made effective as of March 2, 2001 (the "Agreement") by and between Genentech, Inc. ("GNE"), a Delaware corporation with its principal office at 1 DNA Way, South San Francisco, California 94080 and Seattle Genetics, Inc. ("SG"), a Delaware corporation with its principal office at 22215 26th Avenue SE, Bothell, Washington 98021, each on behalf of itself and its Affiliates. GNE and SG are sometimes referred to herein individually as a "Party" and collectively as the "Parties," and references to "GNE" and "SG" shall include their respective Affiliates.
7,000,000 Shares Seattle Genetics, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 5th, 2004 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York
Seattle Genetics, Inc., a Delaware corporation (the “Company”) proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representatives (the “Representatives”), an aggregate of 7,000,000 shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 1,050,000 shares (the “Option Shares”) of Common Stock from the Company. The Firm Shares and the Option Shares are collectively called the “Shares.”
LICENSE AGREEMENT BETWEEN BRISTOL-MYERS SQUIBB AND COMPANY SEATTLE GENETICS, INC. DATED AS OF MARCH 30, 1998License Agreement • February 23rd, 2001 • Seattle Genetics Inc /Wa • Services-commercial physical & biological research • New York
THIS LICENSE AGREEMENT (this "Agreement") dated as of March 30, 1998 by and between Bristol-Myers Squibb Company, a corporation duly organized and existing under the laws of the State of Delaware, having offices at P.O. Box 4000, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, for and on behalf of itself and its Affiliates ("BMS"), and Seattle Genetics, Inc., a corporation duly organized and existing under the laws of the State of Delaware, having offices at 22215 26th Avenue, SE, Bothell, Washington 98021 ("SGI").
LICENSE AGREEMENT No. 651-O1.LICLicense Agreement • November 26th, 2010 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Arizona
THIS AGREEMENT (the “Agreement”), made this 3rd day of February, 2000 (the “EFFECTIVE DATE”), is by and between the ARIZONA BOARD OF REGENTS, a body corporate of the State of Arizona, acting on behalf of and for ARIZONA STATE UNIVERSITY, of Tempe, Arizona (“ASU”) and Seattle Genetics, Inc., a corporation organized under the laws of Delaware having its principal place of business located at 22215 26th Avenue SE, Bothell, Washington 98021 (“LICENSEE”).
CONFIDENTIAL -vi- [*] = Certain information contained in this document, marked by brackets, has been omitted because it is both not material and would be competitively harmful if publicly disclosed. INDEX OF DEFINED TERMS Adverse Event...Joint Commercialization Agreement • February 12th, 2021 • Seagen Inc. • Biological products, (no disgnostic substances) • New York
QuickLinks -- Click here to rapidly navigate through this documentSeattle Genetics Inc /Wa • February 23rd, 2001 • Services-commercial physical & biological research • California
This Agreement, dated as of 24 January 2000 is between Genentech, Inc., a Delaware corporation having a principal place of business 1 DNA Way, South San Francisco, California 94080 (hereinafter "Genentech") and Seattle Genetics Inc., having a place of business at 22215 26th Ave. S.E. Bothell, WA 98021 (hereinafter "Licensee').
COLLABORATION AGREEMENTCollaboration Agreement • March 6th, 2001 • Seattle Genetics Inc /Wa • Services-commercial physical & biological research • New York
THIS COLLABORATION AGREEMENT ("Agreement") is made and entered into effective as of February 2, 2001 (the "Effective Date"), by and between SEATTLE GENETICS, INC., having principal offices at 22215 26th Avenue S.E., Suite 3000, Bothell, WA 98021 ("Seattle Genetics") and MEDAREX, INC., having principal offices at 707 State Road, Suite 206, Princeton, New Jersey 08540-1437, on behalf of itself and its wholly owned subsidiary, GENPHARM INTERNATIONAL, INC., with principal offices at 2350 Qume Drive, San Jose, California 95131 (collectively, "Medarex"). Seattle Genetics and Medarex each may be referred to herein individually as a "Party," or collectively as the "Parties."
LICENSE AGREEMENTLicense Agreement • April 26th, 2018 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York
This License Agreement (this “Agreement”), entered into as of December 11, 2014 (the “Effective Date”), is made by and between Array BioPharma Inc., a Delaware corporation, having offices at 3200 Walnut Street, Boulder, Colorado 80301, and Oncothyreon Inc., a Delaware corporation, having offices at 2601 Fourth Ave., Suite 500, Seattle WA 98121.
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • August 2nd, 2005 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York
• SEATTLE GENETICS, INC., a Delaware corporation, having its principal place of business at 21823 30th Drive S.E., Bothell, Washington 98021 (hereinafter referred to as “Licensor”); and
